Skip to content

Retrieval of Hepatitis C Patients Lost to Follow-up

A Clinical Trial to Evaluate the Efficacy of Two Strategies to Linkage to Care Patients With Hepatitis C Lost to Follow-up

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04153708
Enrollment
352
Registered
2019-11-06
Start date
2019-11-03
Completion date
2021-09-01
Last updated
2021-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Keywords

hepatitis C, lost to follow-up, microelimination

Brief summary

The main purpose of the study is to compare the efficacy of two strategies aimed to rescue patients lost to follow-up with active infection or with positive HCV antibodies without RNA request to complete evaluation and prescription of treatment in cases of chronic infection. After patient identification from data files of laboratory and microbiology charts, patients will be randomized to: a) phone call, and b) invitation letter, both of two strategies including a scheduled appointment with the hepatologist.

Detailed description

This is a prospective, randomized study in which subjects lost to follow-up with positive HCV antibodies without RNA request or positive RNA will be proposed to be brought back into care. After patients identification from data files of laboratory and microbiology charts using three different cohorts in time (2005-07, 2011-11 and 2015-17), eligible patients (18 years of age or older, patients positive for HCV antibodies without RNA request or positive RNA lost to follow-up, with a valid sanitary card in our public health system and with available data for contact) will be randomized to: a) phone call (Strategy 1), and b) invitation letter (Strategy 2), both of two strategies including a scheduled appointment with the hepatologist. Strategy 1 includes until three phone calls to contact patients and provide them with an appointment with the hepatologist (tertiary care center) over a period of 14 days according to patient availability. Instead, strategy 2 includes an invitation letter providing patients with the appointment with the hepatologist over a same period of time than strategy 1. If there is no response to calls or no attendance to the appointment after the letter (randomized strategy), the strategy will be switched to the another one. Epidemiological, clinical, and laboratory variables will be registered. The hypothesis of the study is that phone calls will improve the rate of linkage to care among HCV patients lost to follow-up compared to the invitation letter shipment. Therefore, call would be an effective strategy to rescue these patients. For the present study, a 15% of improvement in linkage to care was hypothesized in the group of patients receiving the strategy 1 compared with the strategy 2. Taking into account a power of 80%, alpha error of 5% and losses of 10% will require 176 patients per strategy.

Interventions

BEHAVIORALRetrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.

Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.

BEHAVIORALRetrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter

Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.

Sponsors

University of La Laguna
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients will be randomized to either call or mail invitation

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. 18 years of age or older 2. Record of positive HCV antibodies without RNA request or positive RNA lost to follow-up (non-treated patients with an active infection, without surveillance by any HCV specialist) 3. Patients a valid sanitary card in our public health system 4. Patients with available data for contact)

Exclusion criteria

1. Belong to another catchment area. Current surveillance by any HCV specialist and/or record of sustained virological response. 2. Severe comorbidity with an expected survival lower than 1 year.

Design outcomes

Primary

MeasureTime frameDescription
Acceptance of the interventionOne month after the interventionNumber of patients and % attending the clinic (linkage to care rate)

Secondary

MeasureTime frameDescription
Effectiveness of the intervention6 months after starting treatmentNumber of patients and % that cure the infection due to intervention (complete assessment and treatment rate).
Viability of the intervention1 weekNumber of patients with unavailable or inaccurate data for contact
Factors associated with viability of the strategies6 monthsRate of patients with predictive factors associated to outcome 1

Countries

Spain

Contacts

Primary ContactManuel Hernandez-guerra, MD
mhernand@ull.edu.es666866237

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026